Sumitomo Chemical Company, Limited (SOMMY) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

As it is time to start, we will now begin the conference call for the presentation of financial results for the fiscal year 2025 second quarter. Thank you very much for your participation. Today, Mr. Sasaki, representative director and senior managing executive officer, will give a briefing on the financial results for fiscal year 2025 second quarter. Later, he will be joined by Mr. Yamauchi, Executive Officer and General Manager of Accounting Department, to take questions. We will conclude the call at 4.50. Mr. Sasaki, over to you. Thank you. I'm Sasaki from Sumitomo Chemical. Thank you very much for attending our conference call today, despite your busy schedule. I'd like to thank our investors and analysts for your daily understanding and support to our management. Thank you very much for that. Now, let me start with a presentation of financial results for fiscal year 2025 second quarter. Please turn to page four. This is a summary page. Core operating income and net income attributable to owners of a parent significantly improved compared to the same period of the previous year. Corporate income of essential green materials increased significantly year over year. There were also profits at Sumitomo Pharma with strong sales results, leading to recording of a sales milestone of Orgovix and partial divestiture of the Asian business. Compared to the forecast announced in August, in addition to strong sales at Semitomo Pharma, there was improvements in foreign exchange gain or loss from Mayan weaker than anticipated, as well as a reduction in the deferred tax liability resulting in a reduction in the corporate income tax expenses, leading to increase in both core operating income and net profit. Please turn to page 5. Consolidated financial results of a second quarter...